Low-dose and high-dose naltrexone in opioid dependence syndrome: a three months outcome study
Background: Naltrexone is effective in the treatment of opioid dependence syndrome (ODS) as it prevents relapse. To effectively design a cost-effective treatment modality for ODS using naltrexone as low as 25 mg is something which is worth exploring. Aim: To study the effectiveness of 25 mg naltrexo...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Academy Publisher
2019-06-01
|
| Series: | Open Journal of Psychiatry and Allied Sciences |
| Subjects: | |
| Online Access: | https://www.ojpas.com/get_file.php?id=33464687&vnr=105408 |
| _version_ | 1818131819148607488 |
|---|---|
| author | Ajeet Sidana Subhash Das Sai Prashant Bansal |
| author_facet | Ajeet Sidana Subhash Das Sai Prashant Bansal |
| author_sort | Ajeet Sidana |
| collection | DOAJ |
| description | Background: Naltrexone is effective in the treatment of opioid dependence syndrome (ODS) as it prevents relapse. To effectively design a cost-effective treatment modality for ODS using naltrexone as low as 25 mg is something which is worth exploring. Aim: To study the effectiveness of 25 mg naltrexone and 50 mg naltrexone in patients with ODS. Materials and methods: Case record files of patients of ODS admitted in psychiatry ward from January 2015 to September 2017 were retrieved and analysed after applying coding plan. Results: A total of 79 patients with ODS were admitted during this period. Patients were divided into three groups- group one received 25 mg naltrexone per day, group two: 50 mg naltrexone, and group three: non-naltrexone. Cumulative abstinence duration (CAD) in group one was 48 days, group two was 52 days, and group three was 23 days. At follow-up, there was no relationship between abstinence status and dose of naltrexone prescribed and amount of opioid use. Conclusion: Naltrexone is effective in reduction of craving and there was no significant difference between the different dosages of naltrexone, i.e. 25 mg and 50 mg per day. |
| first_indexed | 2024-12-11T08:26:59Z |
| format | Article |
| id | doaj.art-7b1aaab0b19e4c95ad2c5ce653f13de3 |
| institution | Directory Open Access Journal |
| issn | 2394-2053 2394-2061 |
| language | English |
| last_indexed | 2024-12-11T08:26:59Z |
| publishDate | 2019-06-01 |
| publisher | Academy Publisher |
| record_format | Article |
| series | Open Journal of Psychiatry and Allied Sciences |
| spelling | doaj.art-7b1aaab0b19e4c95ad2c5ce653f13de32022-12-22T01:14:31ZengAcademy PublisherOpen Journal of Psychiatry and Allied Sciences2394-20532394-20612019-06-0110215115410.5958/2394-2061.2019.00033.8Low-dose and high-dose naltrexone in opioid dependence syndrome: a three months outcome studyAjeet Sidana0Subhash Das1Sai Prashant Bansal2Department of Psychiatry, Government Medical College & Hospital, Chandigarh, IndiaDepartment of Psychiatry, Government Medical College & Hospital, Chandigarh, IndiaGovernment Medical College & Hospital, Chandigarh, IndiaBackground: Naltrexone is effective in the treatment of opioid dependence syndrome (ODS) as it prevents relapse. To effectively design a cost-effective treatment modality for ODS using naltrexone as low as 25 mg is something which is worth exploring. Aim: To study the effectiveness of 25 mg naltrexone and 50 mg naltrexone in patients with ODS. Materials and methods: Case record files of patients of ODS admitted in psychiatry ward from January 2015 to September 2017 were retrieved and analysed after applying coding plan. Results: A total of 79 patients with ODS were admitted during this period. Patients were divided into three groups- group one received 25 mg naltrexone per day, group two: 50 mg naltrexone, and group three: non-naltrexone. Cumulative abstinence duration (CAD) in group one was 48 days, group two was 52 days, and group three was 23 days. At follow-up, there was no relationship between abstinence status and dose of naltrexone prescribed and amount of opioid use. Conclusion: Naltrexone is effective in reduction of craving and there was no significant difference between the different dosages of naltrexone, i.e. 25 mg and 50 mg per day.https://www.ojpas.com/get_file.php?id=33464687&vnr=105408PsychiatryCravingDosage |
| spellingShingle | Ajeet Sidana Subhash Das Sai Prashant Bansal Low-dose and high-dose naltrexone in opioid dependence syndrome: a three months outcome study Open Journal of Psychiatry and Allied Sciences Psychiatry Craving Dosage |
| title | Low-dose and high-dose naltrexone in opioid dependence syndrome: a three months outcome study |
| title_full | Low-dose and high-dose naltrexone in opioid dependence syndrome: a three months outcome study |
| title_fullStr | Low-dose and high-dose naltrexone in opioid dependence syndrome: a three months outcome study |
| title_full_unstemmed | Low-dose and high-dose naltrexone in opioid dependence syndrome: a three months outcome study |
| title_short | Low-dose and high-dose naltrexone in opioid dependence syndrome: a three months outcome study |
| title_sort | low dose and high dose naltrexone in opioid dependence syndrome a three months outcome study |
| topic | Psychiatry Craving Dosage |
| url | https://www.ojpas.com/get_file.php?id=33464687&vnr=105408 |
| work_keys_str_mv | AT ajeetsidana lowdoseandhighdosenaltrexoneinopioiddependencesyndromeathreemonthsoutcomestudy AT subhashdas lowdoseandhighdosenaltrexoneinopioiddependencesyndromeathreemonthsoutcomestudy AT saiprashantbansal lowdoseandhighdosenaltrexoneinopioiddependencesyndromeathreemonthsoutcomestudy |